Patrick W Serruys

Type: Person
Name: Patrick W Serruys
First reported Sep 24 2014 - Updated Sep 24 2014 - 1 reports

ABSORB II Study Shows Abbott's Dissolving Heart Device Comparable to the World's Leading Heart Stent

— Abbott announced positive one-year clinical results from ABSORB II, the world's first prospective, randomized, controlled trial comparing the safety and effectiveness of the dissolving Absorb heart device to Abbott's market-leading metallic XIENCE family ... [Published Diagnostic & Invasive Cardiology - Sep 24 2014]
First reported Sep 17 2014 - Updated Sep 17 2014 - 1 reports

Abbott Issues Absorb II Study Results

Abbott reported positive one-year clinical results from Absorb II, the world's first prospective, randomized, controlled trial comparing the safety and effectiveness of the dissolving Absorb heart device to Abbott's metallic Xience family of DES. The ... [Published Individual.com - Sep 17 2014]
First reported Sep 15 2014 - Updated Sep 15 2014 - 1 reports

TCT.14: Bioresorbable scaffolds appear safe at one year

WASHINGTON, D.C.—Fewer patients with coronary artery disease who were treated with a bioresorbable scaffold experienced new or worsening angina after treatment than similar patients implanted with metal stents in the ABSORB II trial. The one-year results ... [Published Cardiovascular Business - Sep 15 2014]
First reported Sep 14 2014 - Updated Sep 15 2014 - 1 reports

ABSORB II Study Shows Abbott's Dissolving Heart Device Comparable to the World's Leading Heart Stent

WASHINGTONAt one year, overall clinical outcomes for Absorb were comparable to XIENCE, and people treated with Absorb experienced a significantly lower rate of angina (chest pain), a novel finding given the impact of angina on people's quality of life ... [Published Bio-Medicine - Sep 14 2014]
First reported Sep 09 2014 - Updated Sep 09 2014 - 1 reports

TCT 2014 Late-breaking Trials and First Report Investigations

Transcatheter Cardiovascular Therapeutics (TCT) has announced the late-breaking trial presentations at TCT 2014, Sept. 13-17.Late-breaking clinical trials are typically first-time international or U.S. presentations of the primary endpoint or important ... [Published Diagnostic & Invasive Cardiology - Sep 09 2014]
First reported Sep 03 2014 - Updated Sep 03 2014 - 1 reports

The Impact of Renal Impairment on Long-Term Safety and Effectiveness of Drug-Eluting Stents

by Giulio G. Stefanini, Masanori Taniwaki, Bindu Kalesan, Lorenz Räber, Stefan Stortecky, Thomas Pilgrim, Yoshinobu Onuma, Sigmund Silber, Patrick W. Serruys, Bernhard Meier, Peter Jüni, Stephan WindeckerBackgroundRenal impairment (RI) is associated with ... [Published Plosone.org - Sep 03 2014]

More Content

All (8) | News (8) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
ABSORB II Study Shows Abbott's Dissolving Heart... [Published Diagnostic & Invasive Cardiology - Sep 24 2014]
Abbott Issues Absorb II Study Results [Published Individual.com - Sep 17 2014]
TCT.14: Bioresorbable scaffolds appear safe at ... [Published Cardiovascular Business - Sep 15 2014]
ABSORB II Study Shows Abbott's Dissolving Heart... [Published Bio-Medicine - Sep 14 2014]
ABSORB II Study Shows Abbott's Dissolving Heart... [Published ADVFN India - Sep 14 2014]
ABSORB II Study Shows Abbott's Dissolving Heart... [Published Industrial Info Financials - Sep 14 2014]
TCT 2014 Late-breaking Trials and First Report ... [Published Diagnostic & Invasive Cardiology - Sep 09 2014]
The Impact of Renal Impairment on Long-Term Saf... [Published Plosone.org - Sep 03 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.